Rozanolixizumab

Phase 3

UCB (UCBJY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

UCBJYPhase 3$46.1B

Rozanolixizumab Phase 3 Est. Readout

Rozanolixizumab• Generalized Myasthenia Gravis113

Q2 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Generalized Myasthenia Gravis

View Full Landscape

Drug Information

Target Indication

Generalized Myasthenia Gravis

Clinical Trial

NCT05681715

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA1/5/2024

Rystiggo

Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

UCBJY

UCB

Healthcare•North America•NASDAQ

Related Pipeline

SPM 927Phase 3

Partial Seizures With or Without Secondary Generalization

CimziaPhase 3

Crohn Disease

EtanerceptPhase 3

Psoriasis

Certolizumab PegolPhase 3

Rheumatoid Arthritis

Antiepileptic drugs with market authorization available per countryPhase 3

Epilepsy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts